BIDMC researchers develop decision-making tool to benefit patients with HCV

(Beth Israel Deaconess Medical Center) BIDMC researchers led a retrospective analysis of four randomized clinical trials focused on the effects of DAA therapies in patients with HCV-associated liver failure, and developed a new means of predicting improvement in liver function in response to DAA treatment.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news